Introduction
The anthracycline doxorubicin (Dox) is a highly effective anti-neoplastic drug used against many cancers. However, the cumulative dosage of Dox in clinical situations is limited due to serious cardiotoxic side effects. For example, in phase III clinical trials the frequency of congestive heart failure escalated in a dose-dependent manner with an observed 5% frequency at a cumulative anthracylcine dose of 400 mg/m 2 body surface area, 26% at 550 mg/m 2 , and 48% at 700 mg/m 2 (Swain et al., 2003) . Further, less obvious effects occur with exposure to anthracyclines. For example, chronic left ventricular dysfunction was detected in over 50% of asymptomatic patients treated with Dox (Gottdiener et al., 1981) . These subclinical effects contribute to an inability of the heart to adapt to existing or subsequent cardiovascular disease (Priebe, 2000; Schultz et al., 2003) . Due to this cardiotoxicity, a number of therapeutic strategies have been explored to decrease Dox-induced damage to the heart. One such strategy is the use of anthracycline congeners with reduced cardiotoxic potential (Frishman et al., 1996) . One promising, modified anthracycline we have studied is N-benzyladriamycin-14-valerate, referred to as AD 198.
AD 198 was initially developed to circumvent mechanisms of multidrug resistance that impede successful treatment of cancer (Lothstein et al., 1998; Barrett et al., 2002; Bilyeu et al., 2004) . Thus far it has been demonstrated AD 198 overcomes drug resistance of certain tumors, and has comparable tumor cytotoxicity to Dox both in vitro and in vivo (Sweatman and Israel, 1996) . Further, AD 198 does not have the very serious cardiotoxic effect of standard anthracyclines, and even appears to protect the heart from ischemic-reperfusion injury (Hofmann et al., 2007) . These non-cardiotoxic and cardioprotective traits are likely due to the ability of AD 198 to induce activation of PKC-ε (Hofmann et al., 2007) . In the present study, we wished to expand on these studies and determine if co-therapy of AD 198 plus Dox protects the JPET #167965-R2
heart from Dox-induced cardiotoxicity, and to identify molecular factors that may contribute to any cardioprotective effects of AD 198. The impetus for such a study was the hope that using low-dose AD 198 to counter anthracycline toxicity would prove to be of such apparent benefit that Dox plus AD 198 will become the standard of care in treatment for a wide range of cancers.
Methods
Chemicals and Reagents. Dox was purchased from Sigma-Aldrich (St. Louis, MO) and AD 198 hydrochloride salt was prepared according to previously described procedures (Lothstein et al., 1998) . Dox was formulated in sterile saline while AD 198 was formulated in ethanol and polyethylene glycol. The chemical structure of AD 198 can be found in Hofmann et al., 2007. Primary antibodies utilized were phosphorylated AMP kinase (P-AMPK; Cell Signaling #2535; 1:1000 dilution), AMP kinase (AMPK; Santa-Cruz #25792; 1:500 dilution), brain creatine kinase (BCK; Santa-Cruz #15160; 1:500 dilution), inducible nitric oxide synthase (iNOS; SantaCruz #651; 1:500 dilution), poly ADP-ribose polymerase (PARP; Cell Signaling #9542; 1:1000 dilution), phosphorylated troponin I (P-TnI; Cell Signaling #4004; 1:2000 dilution), TnI (SantaCruz #8118; 1:2000 dilution), β-myosin heavy chain (β-MHC; Chemicon #MAB1628; 1:1000 dilution), phosphorylated phospholamban (P-PLB; Millipore #07-052; 1:1000 dilution), PLB Cardiac Myocytes. Ventricular myocytes were isolated from untreated rats using the procedure of Leary et al (2008) . Suspended cells were incubated for 20 min in the presence and absence of 1 μM of the myristoylated PKC-ε V1-2 peptide inhibitor (ENZO Life Science).
Subsequently, vehicle, Dox (1 μM) and/or AD 198 (0.1 μM) were added to the cell suspension.
After 60 min Laemmli electrophoretic sample buffer with phosphatase inhibitor cocktail (Sigma Chemical P2850) was added to stop any reactions and for cell storage.
Protein Preparation and Western Blots. For whole animal/heart studies, at sacrifice hearts were minced and homogenized in a buffer containing 50 mM HEPES, 1mM EDTA, 2 mM dithiothreitol, 10 nM okadaic acid and 1% protease inhibitor cocktail. Homogenates were then incubated on ice for 30 minutes and centrifuged twice at 10,000g for 10 min. The supernatant was collected, and the protein concentration determined using the Bradford assay (Bio-Rad).
Equal amounts of protein, 10 µg / gel lane, were separated by SDS-PAGE and transferred to PVDF membranes. For cardiac myocyte studies an equal amount of cells from each group were collected and run on SDS-APGE and transferred. Membranes were incubated with primary antibody, washed with TBS-T, and exposed to secondary peroxidase-coupled antibodies
(1:8000 dilution). Signals were detected using an enhanced chemiluminescence kit (Pierce Chemical 
Results
Protein Expression and Phosphorylation from In Vivo Animal Studies. Body and heart weights were not statistically different between the animal treatment groups at the time of sacrifice (Table 1) . However, it is interesting to note the trend in decreased body weight of Dox treated compared to Vehicle treated animals. This is likely due to the loss of appetite Cardiac lysates from the 4 treatment groups were used to measure P-AMPK, AMPK, and BCK ( Figure 2 ). These kinases have been associated with energy balance in the heart.
Using the phosphosite-specific antibody against phospho-Thr 172 of P-AMPK, we observed a 45% decrease in P-AMPK induced by Dox that was reversed by co-administration of AD 198. 
Discussion
In the present study we found many, but not all, of the Dox-induced changes in select myocardial proteins were blocked or reversed by co-treatment with AD 198 (Table 2) . AD 198 attenuation of Dox effects appear, in part, to be due to it's ability to activate PKC-ε. In addition,
we found that both the Dox-induced (1) decrease in left ventricular developed pressure and (2) exaggerated responsiveness to Ca 2+ overload in excised hearts were not present in hearts from rats that had been co-treated with AD 198 (Figs 7-9) . Thus, our studies support the idea that some of the underlying molecular and functional changes induced in hearts that have been exposed to Dox can be blocked or reversed by low dose, co-treatment with the modified anthracycline AD 198.
Albumin content was reduced in whole blood samples of animals that were Dox treated ( Figure 1 ). This effect has been previously documented (Iliskovic et al., 1998) .
Hypoalbuminemia is associated with reduced survival in heart failure patients (Horwich et al., 2008) . Mechanisms that may contribute to this include increased atrial fibrillation, a reduction in colloid oncotic pressure leading to pulmonary edema, and/or a reduction in the ability of albumin to be protective in an antioxidant or antiapoptic capacity (Bohm et al., 2009; Horwich et al., 2008) . We found AD 198 co-treatment reversed the Dox effect on albumin concentration. This is consistent with the idea that co-treatment with low levels of AD 198 may protect hearts which have been exposed to Dox. This would lead to an increase in the rate of relaxation and increased Ca 2+ load within the sarcoplasmic reticulum. We found AD 198 co-treatment reversed the Dox effects such that phospho-TnI was increased and phospho-PLB decreased. Both of these effects are consistent with the idea that co-treatment of Dox plus low levels of AD 198 would produce hearts that have a Ca 2+ sensitivity and Ca 2+ handling close to that of hearts which have not been exposed to Dox.
Dox had no effect on desmin expression, but reduced β-tubulin levels and increased β-MHC content ( Figure 5 ). Previously, Dox has been shown to reduce desmin (Fisher et al., 2005) and β-tubulin (Dudnakova et al., 2003) , and increase β-MHC (de Beer et al., 2009 ) content in the heart. The Dox-induced decrease in β-tubulin would alter microtubules that are (1) key to intracellular trafficking of proteins such as connexin 43 and the sodium channel (Smyth et al., 2010; Casini et al., 2010) , and (2) have been implicated as mediators of stress/strain effects in the heart (Iribe et al., 2009) . Microtubule disruption in the heart is associated with cardiac arrhythmias and altered Ca 2+ handling (Smyth et al., 2010; Casini et al., 2010; Iribe et al., 2009 ).
Increased β-MHC is consistent with the onset of a hypertrophic phenotype being induced by an increase in left ventricular diastole diameter (Teraoka et al., 2000) . Thus, caution should be used when comparing our results, using analysis at 3 days post-injection from a single dose of Dox in rats, to humans. Further, we should also note end diastolic pressure post-high Ca 2+ was reduced in the Dox and Dox+AD 198 groups. Although the mechanism and consequences for such an effect is not clear, it appears AD 198 does not reverse this Dox-induced effect.
Multiple mechanisms and targets of Dox contribute to its cardiotoxicity. However, underlying much of the Dox-induced toxicity is its ability to increase reactive oxygen species (ROS; Minotti et al., 2004) . The chemical modifications of Dox that produce AD 198 creates a domain within AD 198 that has a structural similarity to diacyglycerol (DAG), an endogenous ligand for protein kinase C (PKC; Roaten et al., 2001) . We have previously shown AD 198 binds to PKC at its DAG binding site and this activates PKC-ε in cardiomyocytes (Hofmann et al., 2007) . PKC-ε activation is thought to be cardioprotective through its ability to (1) prime sarcolemma K ATP channels to reduce action potential duration and, as such, reduce Ca 2+ entry and Ca 2+ overload, (2) open mitochondrial K ATP channels to prevent Ca 2+ overload and volume overload of the mitochondria, and reduced mitochondrial ROS production, (3) inhibit mPTP opening to inhibit mitochondrial swelling, cytochrome C release, and the uncoupling of oxidative phosphorylation, (4) activate protein phosphatase 1 which decreases phospho-PLB to decrease Ca 2+ content and Ca 2+ cycling thus attenuating any rise in cytosolic [Ca 2+ ], and (5) activate transcription factors which increase anti-oxidant expression to reduce ROS overload (Bolli et al., 2007; Budas et al., 2007) . In a previous study we demonstrated AD 198 protects from ischemia-reperfusion induced cardiac dysfunction, and that this benefit is not observed in PKC-ε knockout mice (Hofmann et al., 2008) . In the present JPET #167965-R2
1 5 study we show PKC-ε inhibition blocks the ability of AD 198 to reverse Dox-induced changes in phosphorylation of AMPK and TnI ( Figure 6 ). These data support an AD 198 -PKC epsilon dependent protective pathway of action. However other current findings, such as the AD 198-induced reversal in hypoalbuminemia (Figure 1) , are hard to envision as attributable to PKC-ε activation and require additional investigation. Studies are also needed to specifically look at Dox pharmacokinetic / distribution in the heart in the presence of AD 198. Although, it is unlikely AD 198 is cardioprotective based solely on a mechanism in which AD 198 displaces Dox binding to targets given Dox cytotoxicity of leukemia cells is not reduced by low doses of AD 198 (unpublished observation). Thus, one mechanism, but not necessarily the only mechanism, of AD 198 effects is through PKC-ε activation.
Finally, consideration of the doses used in the in vivo studies should be considered. A past study demonstrated a single 3 mg/kg dose of AD 198 in rats resulted in an ~20% decrease in mean white blood cell (WBC) count, whereas a single 10 mg/kg dose of DOX produced an ~85% decrease in mean WBC count (Sweatman et al 1999) . With both doses, the rat WBC count returned to normal levels. Thus in the present studies AD 198 is cardioprotective at a dose that has a limited hematotoxicity. This is therapeutically important in considering coadministration of both agents to protect from DOX-induced damage to the heart. In summary, the present studies support the conclusion that in vivo, cardiotoxicity 
